Dedicated to Saving Lives by Transforming At-home Cancer Detection
Clinical laboratory tests save costs and lives by enabling early detection and prevention of disease.
Patients with cancers and other conditions are living longer and enjoying better health because of medical revolutions in diagnostic technology.
At its center are genetic and genomic tests that identify the unique genetic profile of individual patients or their disease and allow physicians to tailor treatment to those unique characteristics.
†
ColoAlert, Lead Product Highlights
Significant Expertise
Founded in 2008 and located in Mainz, Germany – a world-renowned community for advanced DNA and pharmaceutical research.
Managed by Industry Experts
Publicly Listed
A successful IPO in November 2021 (NASDAQ: MYNZ) fuels the progressing commercialisation, product development and research.
Commercially Ready Flagship Product
Our CE-IVD cleared flagship product ColoAlert is the first DNA-based screening test for colorectal cancer in Europe.
Valuable IP Position
Utilizing PCR-based molecular genetics testing for specific DNA tumor markers as well as proprietary mRNA biomarkers for early CRC and AA detection.
MAINZ BIOMED (NASDAQ: MYNZ) AIMS TO BECOME A LEADER IN THE MULTI-BILLION-DOLLAR COLORECTAL CANCER DIAGNOSTICS MARKET
Title | Last Updated | File Size | View |
---|---|---|---|
Board Rules: Mainz Biomed | 30th October 2021 | 300KB | |
Audit Committee Charter | 30th October 2021 | 326KB | |
Compensation Committee Charter | 30th October 2021 | 138KB | |
Nomination Committee Charter | 30th October 2021 | 151KB | |
Foreign Board Diversity Matrix | 28th October 2022 | 121KB |
Title | Last Updated | File Size | View |
---|---|---|---|
Code of Ethics and Business Conduct | 30th October 2021 | 130KB | |
Remuneration Policy | 30th October 2021 | 185KB | |
Remuneration Proposal | 30th October 2021 | 146KB |
Yi Chen, Ph.D. CFA
Raghuram Selvaraju, Ph.D.
To contact our Investor Relations team, send us a message using the form or use one of the other methods below.
Call Length: 60 Minutes
Date and Time: Tuesday July 12, 2022, 4:00 PM EST
Participants: Guido Baechler, CEO & Bill Caragol, CFO
To Listen: Click Here
Suspendisse et blandit nibh. Donec sed erat tempor, vulputate felis at, molestie mi. Proin vitae laoreet purus. Aliquam tempor vestibulum tristique. Ut mollis dui et ante congue, quis consectetur erat venenatis. Nulla eget tempor augue, id porta arcu. Vestibulum vulputate semper augue id condimentum. Ut malesuada vitae diam ut venenatis. Etiam sed erat eu eros fermentum facilisis sit amet sed elit. Curabitur luctus dapibus eleifend. Proin eget mauris velit. Maecenas tincidunt erat ex, efficitur euismod tortor aliquam vel. Ut nec diam et ligula aliquet finibus nec a massa. Etiam at dolor sem. Morbi viverra orci sollicitudin enim sollicitudin, quis lobortis justo pretium. Phasellus ligula eros, hendrerit sed luctus a, pharetra vel arcu.
Aenean commodo, lectus id faucibus fermentum, velit felis euismod turpis, et fermentum turpis ante gravida mauris. Aenean id magna at erat interdum feugiat eu id erat. Duis sed nisi in ex sollicitudin suscipit. Curabitur hendrerit elementum lectus in volutpat. Aenean iaculis, risus ut consequat hendrerit, purus diam tristique mauris, nec consectetur magna tortor quis lectus. Proin varius pulvinar mi at congue. Curabitur non nisl nisl. Fusce ultrices malesuada dui, quis ultrices enim rutrum fermentum.
Q4 2020 – FILING TYPE A
Q3 2020 – FILING TYPE A
Q2 2020 – FILING TYPE A
Q1 2020 – FILING TYPE A
Q4 2019 – FILING TYPE A
Q3 2019 – FILING TYPE A
Q2 2019 – FILING TYPE A
Q1 2019 – FILING TYPE A
H2 2020 – FILING TYPE B
H1 2020 – FILING TYPE B
H2 2019 – FILING TYPE B
H1 2019 – FILING TYPE B
Suspendisse et blandit nibh. Donec sed erat tempor, vulputate felis at, molestie mi. Proin vitae laoreet purus. Aliquam tempor vestibulum tristique. Ut mollis dui et ante congue, quis consectetur erat venenatis. Nulla eget tempor augue, id porta arcu.
CONTACT INFORMATION
CONTACT INFORMATION
CONTACT INFORMATION
CONTACT INFORMATION
If you would like to be kept up to date with the very latest news, please enter your details in the form and we will keep you updated.